Controversies over the staging of alpha-synuclein pathology in Parkinson's disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

26 citing papers in PubMed.

1. The 'α-synucleinopathy syndicate': multiple system atrophy and Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024
   Review
2. Emerging perspectives on precision therapy for Parkinson's disease: multidimensional evidence leading to a new breakthrough in personalized medicine.Frontiers in aging neuroscience · 2024
   Review
3. Shrinkage of olfactory amygdala connotes cognitive impairment in patients with Parkinson's disease.Cognitive neurodynamics · 2023
   Article
4. Activation of α7nAChR Protects Against Gastric Inflammation and Dysmotility in Parkinson's Disease Rats.Frontiers in pharmacology · 2021
   Article
5. Lipid and Lipid Raft Alteration in Aging and Neurodegenerative Diseases: A Window for the Development of New Biomarkers.International journal of molecular sciences · 2019
   Review
6. Infection with mosquito-borne alphavirus induces selective loss of dopaminergic neurons, neuroinflammation and widespread protein aggregation.NPJ Parkinson's disease · 2019
   Article
7. Bidirectional Neural Interaction Between Central Dopaminergic and Gut Lesions in Parkinson's Disease Models.Molecular neurobiology · 2018
   Article
8. Parkinson's disease: what the model systems have taught us so far.Journal of genetics · 2018
   Review
9. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?BMC medicine · 2018
   Article
10. Changes in Cortical Thickness in Patients With Early Parkinson's Disease at Different Hoehn and Yahr Stages.Frontiers in human neuroscience · 2018
    Article
11. Exploring Braak's Hypothesis of Parkinson's Disease.Frontiers in neurology · 2017
    Review
12. Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology.Acta neuropathologica · 2016
    Article
13. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.Acta neuropathologica · 2016
    Review
14. Neuropathobiology of non-motor symptoms in Parkinson disease.Journal of neural transmission (Vienna, Austria : 1996) · 2015
    Review
15. Assessment of brainstem function with auricular branch of vagus nerve stimulation in Parkinson's disease.PloS one · 2015
    Observational
16. Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process.Brain : a journal of neurology · 2014
    Article
17. Interaction between pathogenic proteins in neurodegenerative disorders.Journal of cellular and molecular medicine · 2012
    Review
18. Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy.Journal of neural transmission (Vienna, Austria : 1996) · 2012
    Article
19. Pharmacological therapy in Parkinson's disease: focus on neuroprotection.CNS neuroscience & therapeutics · 2011
    Review
20. Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.Journal of neurochemistry · 2011
    Review

Corrections and comments

• Comment on
  Where does parkinson disease pathology begin in the brain?2002
• Comment on
  Pathology associated with sporadic Parkinson's disease--where does it end?2006
• Comment on
  Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease.2008
• Comment on
  Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance.2008
• Comment on
  The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease.2008
• Comment on
  Staging of brain pathology related to sporadic Parkinson's disease.

Authors and funding

4 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as